

## Appendix B

Ex.	Description	Pages
1	Andersen, Kristoffer A A et al. “Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.” <i>Acta psychiatrica Scandinavica</i> vol. 143,2 (2021): 101-118. doi:10.1111/acps.13249	18
2	Alexander M. Sherwood, Adam L. Halberstadt, Adam K. Klein, John D. McCorvy, Kristi W. Kaylo, Robert B. Kargbo, and Poncho Meisenheimer, <i>Journal of Natural Products</i> 2020 83 (2), 461-467, DOI: 10.1021/acs.jnatprod.9b01061	7
3	Assessment of Abuse Potential of Drugs, Guidance for Industry, FDA (Jan. 2017)	37
4	Averill, Lynnette A, and Chadi G Abdallah. “Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine.” <i>Expert opinion on investigational drugs</i> vol. 31,2 (2022): 133-137. doi:10.1080/13543784.2022.2035358	6
5	Baggott, Matthew J. "Psychedelics and creativity: a review of the quantitative literature." <i>PeerJ PrePrints</i> 3 (2015): e1202v1.	24
6	Baker, Lisa E. “Hallucinogens in Drug Discrimination.” <i>Current topics in behavioral neurosciences</i> vol. 36 (2018): 201-219. doi:10.1007/7854_2017_476	19
7	Basis for the Recommendation to Control Lorcaserin in Schedule IV of the Controlled Substances Act (Jun. 25 2012)	15
8	Basis for the Recommendation to Control Mitragyne and 7-Hydroxymitragine in Schedule I of the Control Substances Act (Oct. 17, 2017)	18
9	Belcher, Sarah. "Here's Why You Shouldn't Do the Nutmeg Challenge on TikTok." <i>Distractify</i> (Apr. 15, 2020)	9
10	Bogenschutz, Michael P, and Matthew W Johnson. “Classic hallucinogens in the treatment of addictions.” <i>Progress in neuro-psychopharmacology &amp; biological psychiatry</i> vol. 64 (2016): 250-8. doi:10.1016/j.pnpbp.2015.03.002	9
11	Borruat, F X et al. “Prolonged visual illusions induced by mefloquine (Lariam): a case report.” <i>Journal of travel medicine</i> vol. 8,3 (2001): 148-9. doi:10.2310/7060.2001.24461	2
12	Carhart-Harris, Robin L, and Guy M Goodwin. “The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.” <i>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</i> vol. 42,11 (2017): 2105-2113. doi:10.1038/npp.2017.84	9
13	Controlled Dangerous Substances, Narcotics and Drug Control Laws: Hearings before the Committee on Ways and Means, House of Representatives, Ninety-First	(Excerpts TBD)

Ex.	Description	Pages
	Congress, Second Session (1970).	
14	Davis, Alan K et al. "Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans." <i>Chronic stress</i> (Thousand Oaks, Calif.) vol. 4 2470547020939564. 8 Jul. 2020, doi:10.1177/2470547020939564	11
15	El-Alfy AT, Wilson L, ElSohly MA, Abourashed EA. Towards a better understanding of the psychopharmacology of nutmeg: Activities in the mouse tetrad assay. <i>J Ethnopharmacol.</i> 2009;126(2):280-286. doi:10.1016/j.jep.2009.08.026	7
16	"FEDERAL DRUG ABUSE AND DRUG DEPENDENCE PREVENTION, TREATMENT, AND REHABILITATION OF 1970," Federal drug abuse and drug dependence prevention, treatment, and rehabilitation act of 1970. Hearings before the Special Subcommittee on Alcoholism and Narcotics of the Committee on Labor and Public Welfare, United States Senate, Ninety-first Congress, second session, S. 3562 .. Part 2 (1970): I-666	(Excerpts TBD)
17	Forrester, Mathias B. "Nutmeg intoxication in Texas, 1998-2004." <i>Human &amp; experimental toxicology</i> vol. 24,11 (2005): 563-6. doi:10.1191/0960327105ht567oa	4
18	Garcia-Romeu A, Davis AK, Erowid E, Erowid F, Griffiths RR, Johnson MW. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <i>Front Psychiatry.</i> 2020;10:955. Published 2020 Jan 22. doi:10.3389/fpsyt.2019.00955	16
19	Garcia-Romeu, Albert et al. "Kratom ( <i>Mitragyna speciosa</i> ): User demographics, use patterns, and implications for the opioid epidemic." <i>Drug and alcohol dependence</i> vol. 208 (2020): 107849. doi:10.1016/j.drugalcdep.2020.107849	8
20	Gatch, Michael B et al. "Discriminative Stimulus Effects of Substituted Tryptamines in Rats." <i>ACS pharmacology &amp; translational science</i> vol. 4,2 467-471. 29 Dec. 2020, doi:10.1021/acsptsci.0c00173	5
21	Giroir, B. Letter to Acting Administrator Dhillon re: Basis for the Recommendation to Control Mitragyne and 7-Hydroxymitragine in Schedule I of the Control Substances Act (Aug. 16, 2018)	4
22	Greenspan, Rachel. "The nutmeg challenge is going viral again on TikTok, and the platform is struggling to remove the dangerous trend." <i>Insider</i> (Apr. 20, 2020).	7
23	Heal, David J et al. "Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans." <i>Neuropharmacology</i> vol. 142 (2018): 89-115. doi:10.1016/j.neuropharm.2018.01.049	27
24	Krediet, Erwin et al. "Reviewing the Potential of Psychedelics for the Treatment of PTSD." <i>The international journal of neuropsychopharmacology</i> vol. 23,6 (2020): 385-400. doi:10.1093/ijnp/pyaa018	16

Ex.	Description	Pages
25	LinkedIn Profile, Theresa Carbonaro	6
26	Memorandum from L. Patrick Gray to Hugh Durham (June 4, 1969)	3
27	Memorandum from Michael R. Sonnenreich to John W. Dean (May 7, 1969)	7
28	Memorandum from Will Wilson to the Attorney General re: Controlled Dangerous Substances Act of 1969 (March 13, 1969)	6
29	Nutt D. Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science". EMBO Rep. 2014;15(3):208-211. doi:10.1002/embr.201338282	4
30	Nutt DJ. "Groundhog decade not brave new world." Drug Science, Policy and Law. January 2020. doi:10.1177/2050324519898963	6
31	Nutt, David et al. "Psychedelic Psychiatry's Brave New World." Cell vol. 181,1 (2020): 24-28. doi:10.1016/j.cell.2020.03.020	5
32	Nutt, David J et al. "Drug harms in the UK: a multicriteria decision analysis." Lancet (London, England) vol. 376,9752 (2010): 1558-65. doi:10.1016/S0140-6736(10)61462-6	9
33	Printouts from <a href="https://tactogen.com/">https://tactogen.com/</a>	(Excerpts TBD)
34	Printouts from <a href="https://www.mindstate.design/">https://www.mindstate.design/</a>	(Excerpts TBD)
35	Rosthal, R. J. (1978) The Administrative Procedure Act. Drug Enforcement 5(2).	11
36	Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV of the Controlled Substances Act	10
37	Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology. 2022;36(3):258-272. doi:10.1177/02698811211069100	15
38	Serafine, Katherine M et al. "Characterization of the discriminative stimulus effects of lorcaserin in rats." Journal of the experimental analysis of behavior vol. 106,2 (2016): 107-16. doi:10.1002/jeab.222	16
39	Testimony of Dr. Lester Grinspoon during Scheduling Hearing of MDMA	6
40	Vodra, W. W. (1975). The controlled substances act. Drug Enforcement, 2(2).	17
41	Williams, E Y, and F West. "The use of nutmeg as a psychotropic drug. Report of two cases." Journal of the National Medical Association vol. 60,4 (1968): 289-90.	2
42	131 Cong. Rec. S17842-04 (Dec. 18, 1985)	12
43	38 Fed. Reg. 27513 (Oct. 4, 1973)	5
44	51 Fed. Reg. 36552 (Oct. 14, 1986)	15
45	63 Fed. Reg. 59751 (Nov. 5, 1998)	32
46	76 Fed. Reg. 77330 (Dec. 12, 2011)	5
47	78 Fed. Reg. 26701 (May 8, 2013)	12